Researchers have patented an innovative molecular test that can measure a genetic mutation linked to both FTD and ALS. Members of the Mayo Clinic’s Neurodegenerative Diseases Lab — led by Leonard Petrucelli, chairman of the neurology department at the clinic’s Florida location — received approval for the patent on September 20. The molecular test (also known as an immunoassay) is able to diagnose properties of the mutated gene C9ORF72, which causes the most common genetic forms of FTD and ALS. Dr. Petrucelli sits on the scientific advisory board of the FTD Biomarkers Initiative.